Fig. 1.

Efficacy of galidesivir against RVFV infection and tolerability in Syrian golden hamsters (experiment 1). A) survival outcome and B) percent weight change of animals challenged SC with RVFV (n = 10/group) that were treated BID with the indicated loading (IP) and maintenance (IM) doses of galidesivir (mg/kg/day) or placebo for 6 days according to Table 1. Ribavirin was administered IP, BID, for 8 days. C) survival outcome and D) percent weight change of uninfected animals (n = 5/group) treated as described in Table 1 to assess the tolerability of galidesivir treatments. The weight data are represented as the group mean and standard error of the mean of the percent change in weight of surviving animals relative to their starting weights on day 0. *P < 0.05, **P < 0.01, ***P < 0.001 compared to animals receiving placebo.